5 days ago · GlaxoSmithKline (GSK) is set to apply artificial intelligence (AI) technology to improve its drug discovery efforts through a collaboration with Cloud Pharmaceuticals. Its deal with the US-based...

Additionally, by gaining an understanding of the structural alterations and interactions between GSK-3β and its inhibitors, this technique can aid in the logical design and optimization of natural compounds as cutting-edge treatments for a variety of illnesses linked to GSK-3β malfunction.

6 days ago · GlaxoSmithKline is investing in artificial intelligence (AI) with the hope of radically cutting the time and money needed to develop a drug.

We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new medicines and vaccines to address the root cause of disease.

GlaxoSmithKline plc (GSK) and Yale University have established a drug discovery research collaboration to design a potential new class of medicines that degrade disease-causing proteins. Issued: London UK and Phildelphia USA.

1 day ago · Shobie Ramakrishnan has helped transform GSK into a data-led company, helping speed up drug discovery. ‘I’m not trying to turn GSK into Google’: How GSK’s Silicon Valley veteran has ...

Mar 13, 2025 · GSK-3β is a highly sought-after target in drug development and its inhibitors are potential candidates for treatment of various diseases. Isonicotinamide derivatives have been proven to be promising leads for GSK-3β inhibitor discovery.

16 hours ago · Shobie Ramakrishnan has helped transform GSK into a data-led company, helping speed up drug discovery.

Therefore, a GSK-3β inhibitor may be a suggested medicine for Alzheimer's therapy. Nowadays, computational techniques are thought to be among the quickest and most affordable options for therapeutic design and drug discovery.

Mar 4, 2025 · In this episode of Eureka!, a McKinsey podcast on innovation in life sciences R&D, hosts Navraj Nagra and Alex Devereson speak to Kim Branson, senior vice president and global head of AI and machine learning at GSK. They discuss how these emerging technologies are being used to potentially reshape how drugs are developed and about the complexities AI and machine learning introduce in data ...